1. Syndecan-4 regulates ADAMTS-5 activation and cartilage breakdown in osteoarthritis
- Author
-
Echtermeyer, Frank, Bertrand, Jessica, Dreier, Rita, Meinecke, Ingmar, Neugebauer, Katja, Fuerst, Martin, Lee, Yun Jong, Song, Yeong Wook, Herzog, Christine, Theilmeier, Gregor, and Pap, Thomas
- Subjects
Cartilage -- Research ,Cartilage -- Physiological aspects ,Gene expression -- Research ,Gene expression -- Physiological aspects ,Osteoarthritis -- Research ,Osteoarthritis -- Genetic aspects - Abstract
Aggrecan cleavage by a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 5 (ADAMTS-5) is crucial for the breakdown of cartilage matrix during osteoarthritis (1,2,) a degenerative joint disease that leads to the progressive destruction of articular structures. The mechanisms of ADAMTS-5 activation and their links to the pathogenesis of osteoarthritis remain poorly understood, but syndecans have been shown to be involved in the activation of ADAMTS-4 (ref. 3). Here we show that syndecan-4 is specifically induced in type X collagen-producing chondrocytes both in human osteoarthritis and in murine models of the disease. The loss of syndecan-4 in genetically modified mice and intra-articular injections of syndecan-4-specific antibodies into wild-type mice protect from proteoglycan loss and thereby prevent osteoarthritic cartilage damage in a surgically induced model of osteoarthritis. The occurrence of less severe osteoarthritis-like cartilage destruction in both syndecan-4-deficient mice and syndecan-4-specific antibody-treated wild-type mice results from a marked decrease in ADAMTS-5 activity. Syndecan-4 controls the activation of ADAMTS-5 through direct interaction with the protease and through regulating mitogen-activated protein kinase (MAPK)-dependent synthesis of matrix metalloproteinase-3 (MMP-3). Our data suggest that strategies aimed at the inhibition of syndecan-4 will be of great value for the treatment of cartilage damage in osteoarthritis., Human osteoarthritis is a common and often debilitating disorder of the joints that in Western populations affects about 15% of all individuals above 60 years of age (4). One main [...]
- Published
- 2009